Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy - a Phase II Trial.

NCT03068416 is registered in ClinicalTrials.gov with Uppsala University as lead sponsor.

NCT NCT03068416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03068416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy - a Phase II Trial.
Lead sponsor
Uppsala University
Phase
Phase 2
Overall status
Completed
Start date
September 18, 2017
Completion date
August 19, 2021
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell leukemia, b-cell lymphoma